Clinical trial · Interventional
Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®)
Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®) for Treatment of Focal Liver Malignancies: A Preliminary Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Increasing ablative zone is an essential part to improve technical success and long term outcome in patient treated with radiofrequency ablation (RFA). A combination of dual switching system and separable clustered electrode has been reported to create large ablative zone in preclinical study. Based on preclinical study, the investigators conducted a preliminary study in eligible 60 patients to measure whether this combination (dual switching system and separable clustered electrode) improves technical success rate and local tumor progression rate over a year, in comparison with historical control group.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DSM | Device | — | UNRESOLVED |
| separable clustered electrode | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- RFA DSM
- description
- Eligible patients who undergo RFA using DSM and separable clustered electrodes.
- interventionNames
- Device: DSM
- Device: separable clustered electrode
- type
- NO_INTERVENTION
- label
- RFA SSM
- description
- Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
Primary outcomes (1)
- measure
- local tumor progression (LTP)
- timeFrame
- 12 months
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma (according to AASLD guideline or LI-RADS) * histologically confirmed HCC * histologically confirmed or typical imaging feature of colorectal cancer liver metastasis in patients with colorectal cancer AND * equal to or larger than 2cm, equal to or smaller than 5cm * available cross-sectional liver imaging within 30 days before RFA * signed informed consent Exclusion Criteria: * history of local treatment on the index tumor * more than three tumors in a patient * tumors in central portion of portal vein or hepatic vein * Child-Pugh class C * vascular invasion by tumors * uncorrected coagulopathy * presence of multiple extrahepatic metastases
References
Publications (0)
Data not yet available